SANTEN, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.santeninc.com
Clinical Trials
53
Trial Phases
4 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Drug: 0.1% STN1013600 ophthalmic solutionDrug: 0.3% STN1013600 ophthalmic solutionDrug: Placebo
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT05665387
- Locations
- 🇺🇸
Global Research Management Inc, Glendale, California, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Drug: STN1010904 ophthalmic suspension 0.1% BIDDrug: Placebo (Vehicle) BIDDrug: STN1010904 ophthalmic suspension 0.03% BID
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT05376176
- Locations
- 🇺🇸
Stein Eye Institution UCLA, Los Angeles, California, United States
🇺🇸Price Vision Group, Indianapolis, Indiana, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionPrimary Open Angle Glaucoma
- Interventions
- Drug: DE-126 Ophthalmic Solution 0.002% QD
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT04742283
- Locations
- 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸Arizona Glaucoma Specialists, Phoenix, Arizona, United States
🇺🇸Walman Eye Center, Sun City, Arizona, United States
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
- Conditions
- Primary Open-angle Glaucoma and Ocular Hypertension
- Interventions
- Drug: DE-117 Ophthalmic Solution QDDrug: DE-117 Ophthalmic Solution BID
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03858894
- Locations
- 🇺🇸
East West Eye Institute, Los Angeles, California, United States
🇺🇸Danbury Eye Specialist, Danbury, Connecticut, United States
🇺🇸Hernando Eye Institute, Brooksville, Florida, United States
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
- Conditions
- Non Infectious Uveitis
- Interventions
- Drug: DE-109 Intravitreal Injections (Open Label)Drug: DE-109 Intravitreal InjectionsOther: Sham Procedure
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT03711929
- Locations
- 🇺🇸
Arizona Retina & Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Kaiser Permanente Medical Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next